Joel E. Segel

Joel E. Segel

Auto-generated profile, based on publicly available information

Joel E. Segel

Department of Health Policy and Administration, Penn State University , University Park, PA 16802

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Diabetes Care
Verified
Journal Article
Open access
PDF file
THThomas J Hoerger
Thomas J Hoerger
JSJoel E Segel
Joel E Segel
EGEdward W Gregg
Edward W Gregg
JSJinan B Saaddine
Jinan B Saaddine
OBJECTIVE—To assess changes in diabetic lower-extremity amputation rates in a defined relatively static population over an 11-year period following the introduction of a multidisciplinary foot team.

1 September 2013 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
AHAmanda A. Honeycutt
Amanda A. Honeycutt
JSJoel E. Segel
Joel E. Segel
XZXiaohui Zhuo
Xiaohui Zhuo
THThomas J. Hoerger
Thomas J. Hoerger
KIKumiko Imai
Kumiko Imai
DWDesmond Williams
Desmond Williams
Estimates of the medical costs associated with different stages of CKD are needed to assess the economic benefits of interventions that slow the progression of kidney disease. We combined laboratory data from the National Health and Nutrition Examination Survey with expenditure data from Medicare claims to estimate the Medicare program’s annual costs that were attributable to CKD stage 1–4. The Medicare costs for persons who have stage 1 kidney disease were not significantly different from zero. Per person annual Medicare expenses attributable to CKD were $1700 for stage 2, $3500 for stage 3, and $12,700 for stage 4, adjusted to 2010 dollars. Our findings suggest that the medical costs attributable to CKD are substantial among Medicare beneficiaries, even during the early stages; moreover, costs increase as disease severity worsens. These cost estimates may facilitate the assessment of the net economic benefits of interventions that prevent or slow the progression of CKD.

1 March 2010 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
THThomas J. Hoerger
Thomas J. Hoerger
JWJohn S. Wittenborn
John S. Wittenborn
JSJoel E. Segel
Joel E. Segel
NBNilka R. Burrows
Nilka R. Burrows
KIKumiko Imai
Kumiko Imai
DWDesmond E. Williams
Desmond E. Williams

1 March 2010 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
THThomas J. Hoerger
Thomas J. Hoerger
JWJohn S. Wittenborn
John S. Wittenborn
JSJoel E. Segel
Joel E. Segel
NBNilka R. Burrows
Nilka R. Burrows
KIKumiko Imai
Kumiko Imai
DWDesmond E. Williams
Desmond E. Williams

30 April 2011 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
PDF file
THThomas J. Hoerger
Thomas J. Hoerger
DEDonatus U. Ekwueme
Donatus U. Ekwueme
JMJacqueline W. Miller
Jacqueline W. Miller
VUVladislav Uzunangelov
Vladislav Uzunangelov
IHIngrid J. Hall
Ingrid J. Hall
CLChunyu Li
Chunyu Li

6 February 2020 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JSJoel E. Segel
Joel E. Segel
ELEugene J. Lengerich
Eugene J. Lengerich
Background: Greater travel time to cancer care has been identified as a potential barrier to care as well as associated with worse health outcomes. While rural cancer patients have been shown to travel farther for care, it is not known what patient, facility, and clinical characteristics may differentially be associated with greater roundtrip travel times for cancer patients by rurality of residence. Identifying these factors will help providers understand which patients may be most in need of resources to assist with travel. Methods: Using 2010–2014 Pennsylvania Cancer Registry data, we examined the association between patient, facility, and clinical characteristics with roundtrip patient travel time using multivariate linear regression models. We then estimated separate models by rural residence based on the Rural-Urban Continuum Code (RUCC) of a patient’s county of residence at diagnosis to understand how the association of each factor with travel time may vary for patients separated into metro residents (RUCC 1–3); and two categories of non-metro residents (RUCC 4–6) and (RUCC 7–9). Results: In our sample (n = 197,498), we document large differences in mean roundtrip travel time—mean 41.5 min for RUCC 1–3 patients vs. 128.9 min for RUCC 7–9 patients. We show cervical/uterine and ovarian cancer patients travel significantly farther; as do patients traveling to higher volume and higher-ranked hospitals. Conclusions: To better understand patient travel burden, providers need to understand that factors predicting longer travel time may vary by rurality of patient residence and cancer type.